CClinicalTrials.gg
Sign In
CompletedNCT04571372Updated Jul 13, 2026

Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor in Valvular Heart Disease

An observational study in Severe Aortic Stenosis or Severe Aortic Regurgitation, sponsored by Yonsei University. Completed at 1 site in South Korea. Open to participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Yonsei University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
222
Ages
19 Years to 99 Years
Sex
All
01

Study summary

This study investigates the association between level of suPAR and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suPARnostic standard enzyme-linked immunosorbent assay (ViroGates, Denmark)

02

Conditions studied

  • Severe Aortic Stenosis or Severe Aortic Regurgitation
03

In context

Aortic Valve Stenosis

985 studies on the registry are indexed under Aortic Valve Stenosis; 283 are open to participants now.

This study's enrollment of 222 is above the median of 200 across 424 observational studies indexed under Aortic Valve Stenosis.

Browse Aortic Valve Stenosis studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,387 studies on the registry; 231 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with severe aortic stenosis or severe aortic regurgitation

Inclusion criteria

  • Age ≥ 19 yrs
  • Severe aortic stenosis or severe aortic regurgitation
  • Agree to consent for self
  • Can follow-up for the next 2 years

Exclusion criteria

Exclusion Criteria:

  • Pre-existing acute kidney injury
  • Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy
  • On ECMO or IABP
  • Life expectancy \< 12 months
  • Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
222 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with severe aortic stenosis or severe aortic regurgitation

    Patients with severe aortic stenosis or severe aortic regurgitation

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse clinical outcomes

    Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

    Time frame: Immediate post operation

  2. Number of participants with adverse clinical outcomes

    Composite of all-cause death, cardiovascular mortality, and worsening of kidney function

    Time frame: 2 years after recruiting

07

Study locations

1 site
  • Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine
    Seoul, South Korea
08

References and documents

Publications

  • Koller L, Stojkovic S, Richter B, Sulzgruber P, Potolidis C, Liebhart F, Mortl D, Berger R, Goliasch G, Wojta J, Hulsmann M, Niessner A. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure. JACC Heart Fail. 2017 Apr;5(4):268-277. doi: 10.1016/j.jchf.2016.12.008. PubMed 28359415 ↗
  • Hayek SS, Sever S, Ko YA, Trachtman H, Awad M, Wadhwani S, Altintas MM, Wei C, Hotton AL, French AL, Sperling LS, Lerakis S, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med. 2015 Nov 12;373(20):1916-25. doi: 10.1056/NEJMoa1506362. Epub 2015 Nov 5. PubMed 26539835 ↗
  • Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS, Sever S, Camacho A, Wang X, Dande RR, Ibrahim NE, Baron RM, Altintas MM, Wei C, Sheikh-Hamad D, Pan JS, Holliday MW Jr, Januzzi JL, Weisbord SD, Quyyumi AA, Reiser J. Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020 Jan 30;382(5):416-426. doi: 10.1056/NEJMoa1911481. PubMed 31995687 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04571372
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Oct 1, 2020
Start date
Aug 14, 2020
Primary completion
Dec 13, 2025
Completion
Dec 13, 2025
Last update
Jul 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Aortic Valve Stenosis→

Other studies from this sponsor

Yonsei University

Start the discussion